This Week in Rheumatology — Jul 16, 2026

Welcome to This Week in Rheumatology. This week we are covering ten notable papers spanning three broad themes: novel therapeutic pathways and real-world outcomes in vasculitis and autoinflammatory diseases, optimized screening and patient-reported measures in myositis and lupus, and the broader clinical and socioeconomic contexts of chronic rheumatic care. Let us dive in.

We begin with major clinical insights into vasculitis management, starting with real-world evidence for avacopan in antineutrophil cytoplasmic antibody-associated vasculitis. In a retrospective single-centre study published in RMD Open, researchers evaluated thirty-five patients with new-onset or relapsing vasculitis who received avacopan alongside standard induction therapies like rituximab, cyclophosphamide, or both, comparing them to seventy matched controls [2]. Although the avacopan group had more severe baseline kidney impairment, with a median estimated glomerular filtration rate of twenty-four millilitres per minute compared to forty-nine in the control group, the results were highly encouraging. While remission rates were similar at six months, they tended to be higher with avacopan at twelve months, reaching eighty-six percent compared to sixty-eight percent in the control cohort. Most notably, the relapse rate was drastically lower in the avacopan group, at sixteen percent versus fifty-one percent in controls. Avacopan also successfully facilitated accelerated glucocorticoid tapering, with patients reaching five milligrams or less of prednisolone per day in roughly one hundred days compared to one hundred and sixty-four days in the control group, resulting in a significantly lower cumulative steroid dose. Renal recovery was also superior, showing a greater improvement in estimated glomerular filtration rate after one year. However, clinicians should remain vigilant, as over a quarter of patients discontinued avacopan due to adverse events.

Staying with vasculitis, diagnostic delay remains a major hurdle in large vessel vasculitis, as highlighted by a retrospective study from a tertiary German rheumatology centre published in RMD Open [10]. Looking at five hundred and one patients, including four hundred and eighty-eight with giant cell arteritis and thirteen with Takayasu arteritis, researchers found a stark difference in the timeline to diagnosis. The median time to diagnosis for Takayasu arteritis was two hundred and forty-five days, nearly three times longer than the eighty-nine days observed for giant cell arteritis. Patients presenting with typical cranial symptoms experienced a significantly shorter diagnostic interval. Conversely, involvement of the aorta and its major branches was linked to prolonged delays, with a hazard ratio of zero point six four. Interestingly, prior consultations with rheumatologists were actually associated with longer diagnostic delays, whereas referrals by ophthalmologists and cardiologists were associated with earlier diagnosis, demonstrating hazard ratios of two point four and three point eight one, respectively. This suggests that atypical, non-cranial presentations often baffle initial providers, and emphasizes the need for broader clinical education to suspect large vessel vasculitis when classic cranial symptoms are absent.

Moving to other targeted therapies, a phase two open-label trial published in Annals of the Rheumatic Diseases evaluated the Bruton's tyrosine kinase inhibitor zanubrutinib for active immunoglobulin G4-related disease, specifically involving the lacrimal and submandibular glands [1]. Ten participants received zanubrutinib monotherapy for up to twenty-four weeks without any glucocorticoid induction or background immunosuppression. At week twenty-four, blinded imaging showed that mean gland volume decreased significantly, by nearly forty-seven percent in the lacrimal glands and thirty percent in the submandibular glands, alongside substantial reductions in metabolic lesion volume and clinical disease activity. Single-cell RNA sequencing revealed that zanubrutinib modulated B-cell transcriptional programmes, reduced immunoglobulin G4-skewed plasmablasts, and attenuated cytotoxic CD4-positive T cells, offering a promising, steroid-sparing therapeutic strategy. Meanwhile, in the realm of monogenic autoinflammatory diseases, real-world data from the international AutoInflammatory Disease Alliance network registry, published in Rheumatology, confirmed the long-term effectiveness of the interleukin-one inhibitor canakinumab in familial Mediterranean fever [8]. Among one hundred and fifty-eight patients, complete clinical and laboratory response was achieved in nearly forty-six percent of patients at three months and almost fifty-nine percent at one year, with more than eighty percent of patients completely free of clinical manifestations across all timepoints. Discontinuation due to inefficacy was rare, and early control at three months was a strong predictor of sustained long-term remission.

Our second major theme focuses on optimizing risk stratification and patient-reported outcomes in myositis and lupus. We begin with a multicentre international audit published in RMD Open, which evaluated historical malignancy screening practices in seven hundred and ninety-five patients with idiopathic inflammatory myopathy against the recently published International Myositis Assessment and Clinical Studies, or IMACS, guidelines [3]. The audit revealed a stark gap in clinical practice: very few high-risk, moderate-risk, or standard-risk patients underwent the full panel of recommended screening tests. Despite this underscreening, nearly eleven percent of the cohort developed a malignancy within three years of myositis diagnosis. Strikingly, over three-quarters of these cancers occurred in patients classified as high-risk, and the remaining occurred in the moderate-risk group, with absolutely no cancers detected in the standard-risk group, strongly validating the IMACS risk stratification framework. Independent risk factors for cancer included anti-transcription intermediary factor one-gamma positivity, smoking, night sweats, and older age, while anti-Mitwo antibodies and non-dermatomyositis subtypes were protective.

Accurate risk assessment is also critical in myositis-associated interstitial lung disease, as demonstrated by a study in RMD Open that evaluated the prognostic value of chest high-resolution computed tomography [9]. Comparing visual assessments against quantitative imaging analysis in one hundred and sixty-eight patients, researchers found that while visual review identified interstitial lung disease in about half of the patients, neither the visual presence nor the specific radiological pattern predicted survival. In contrast, quantitative measures of lung fibrosis and total lung disease burden were strongly correlated with forced vital capacity and diffusing capacity. Crucially, higher baseline quantitative scores and worsening trends within the first twelve months were independent predictors of all-cause mortality. This highlights a clear clinical need to transition from subjective visual reviews to objective quantitative imaging metrics to identify high-risk patients early.

In systemic lupus erythematosus, cognitive dysfunction or brain fog is a highly prevalent and disabling symptom that has historically been difficult to measure. To address this, a study published in Lupus Science and Medicine detailed the international development and validation of the Lupus Brain Fog Severity Scale, which is the first patient-reported outcome measure designed specifically for this symptom [7]. Validated in a cohort of three hundred and seventy-eight patients across thirty-six countries, the scale demonstrated excellent internal consistency and a strong correlation with functional impact and overall symptom severity, providing clinicians with a practical and reliable tool for routine clinical use. Beyond cognitive symptoms, patients with systemic autoimmune diseases face severe long-term complications, including human papillomavirus-induced malignancies. A massive nationwide matched cohort study from France, published in RMD Open, compared over one hundred and twenty-two thousand patients with immune-mediated inflammatory diseases—such as lupus, Sjogren's syndrome, systemic sclerosis, and rheumatoid arthritis—against over three hundred and sixteen thousand matched controls over an eight-year period [4]. The study revealed that patients with these inflammatory conditions have nearly double the risk of developing human papillomavirus-induced cancer or severe dysplasia, with significantly elevated risks for cervical, vulvar, vaginal, and anal cancers. The risk was particularly high among female patients, those with lupus, individuals under sixty-five, and those with chronic kidney disease, emphasizing the critical need for aggressive vaccination and screening in these populations.

Our final theme explores broader management paradigms and systemic factors influencing rheumatology care. First, a clinical review in The New England Journal of Medicine re-evaluates fibromyalgia, emphasizing that the condition is characterized by central nervous system hyperresponsiveness to sensory stimuli [5]. The authors outline that successful management must focus on achieving central nervous system quiescence and restoring homeostasis through a combination of pharmacologic and nonpharmacologic strategies, such as physical exercise and cognitive behavioral therapy. While fibromyalgia is rarely curable, the review highlights that the vast majority of cases can be managed highly effectively within primary care, with rheumatologists serving primarily as diagnostic consultants. Finally, we must consider how national socioeconomic factors influence our treatment outcomes. A study published in Annals of the Rheumatic Diseases analyzed data from nearly thirty-nine thousand patients with psoriatic arthritis or axial spondyloarthritis initiating biologic or targeted synthetic therapies across thirteen European countries [6]. The researchers discovered that drug retention was significantly lower in wealthier countries with a high gross domestic product per capita, where clinicians and patients discontinued or switched therapies much earlier. Conversely, patients in lower-income countries initiated advanced therapies at significantly higher levels of disease activity. This suggests that national economic status and local healthcare resources heavily influence both the threshold for starting advanced therapies and the ease of switching between them, a factor that clinicians and policy makers must keep in mind when interpreting international clinical data.

If you only have time for one paper this week, make it the real-world comparative study of avacopan in ANCA-associated vasculitis published in RMD Open [2]. This study provides vital, real-world confirmation of avacopan's steroid-sparing efficacy and its ability to drastically reduce relapses and improve renal recovery in patients with severe disease, offering immediate practical guidance for our daily clinical decisions.

Here are the key takeaways from this week in Rheumatology. First, in ANCA-associated vasculitis, real-world data confirm that adding avacopan to induction therapy significantly reduces relapses, enhances renal recovery, and dramatically cuts cumulative glucocorticoid exposure, despite a high rate of drug discontinuation due to adverse events. Second, the newly validated Lupus Brain Fog Severity Scale offers a highly reliable, patient-reported tool to measure and track cognitive dysfunction in daily clinical practice. Third, patients with systemic autoimmune diseases, particularly lupus, face double the risk of human papillomavirus-associated cancers, demanding aggressive vaccination and screening strategies. Fourth, quantitative chest computed tomography metrics, rather than visual patterns, are the key predictors of mortality in myositis-associated interstitial lung disease and should be integrated into high-risk patient assessments. And fifth, national socioeconomic factors heavily influence biologic drug retention and disease activity thresholds, with wealthier nations showing earlier drug switching and lower-income nations initiating therapy at higher disease activity levels.

That's your roundup for This Week in Rheumatology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.